Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats

Nephrology Dialysis Transplantation

Volumn 23, Issue 9, 2008, Pages 2750-2760

  Ko, Gang Jee ^a   Kang, Young Sun ^a   Han, Sang Youb ^b   Lee, Mi Hwa ^a   Song, Hye Kyoung ^a   Han, Kum Hyun ^b   Kim, Hyoung Kyu ^a   Han, Jee Young ^c   Cha, Dae Ryong ^a,d  

^a Korea University   (South Korea)

^b Inje University   (South Korea)

^c Inha University   (South Korea)

^d Korea University College of Medicine   (South Korea)

Author keywords

Diabetic nephropathy; Inflammation; Nuclear factor kappa B; PPAR agonist; Type 2 diabetes

Indexed keywords

ALBUMIN; ALPHA2 INTEGRIN; BETA ACTIN; BETA6 INTEGRIN; BONE MORPHOGENETIC PROTEIN 15; CASPASE 3; COLLAGEN TYPE 4; COLONY STIMULATING FACTOR 1; CYTOKINE; FIBROBLAST GROWTH FACTOR 10; GELATINASE B; GLUCOSE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; LIPID; MACROPHAGE MIGRATION INHIBITION FACTOR; MITOGEN ACTIVATED PROTEIN KINASE 11; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN TYROSINE PHOSPHATASE; SOMATOMEDIN B RECEPTOR; SOMATOMEDIN C; SYNAPTOTAGMIN I; THYMOSIN BETA4; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 1; UNINDEXED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE MARKER; DNA MICROARRAY; DOWN REGULATION; DRUG MECHANISM; GEL MOBILITY SHIFT ASSAY; GENETIC TRANSCRIPTION; GLOMERULOSCLEROSIS; GLUCOSE BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INSULIN RESISTANCE; INSULIN SENSITIVITY; KIDNEY CORTEX; KIDNEY INJURY; MACROPHAGE; MALE; MESANGIUM CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RAT; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; URINARY EXCRETION; WESTERN BLOTTING;

ANIMALS; CELLS, CULTURED; CHEMOKINE CCL2; COLLAGEN TYPE IV; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; DOWN-REGULATION; ELECTROPHORETIC MOBILITY SHIFT ASSAY; HYPOGLYCEMIC AGENTS; IMMUNOHISTOCHEMISTRY; INSULIN RESISTANCE; KIDNEY CORTEX; MALE; MESANGIAL CELLS; NF-KAPPA B; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PEPTIDE FRAGMENTS; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMERASE CHAIN REACTION; PROCOLLAGEN; RATS; RATS, INBRED OLETF; THIAZOLIDINEDIONES;

EID: 56949105387     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn157     Document Type: Article

References (35)

1. Centers for Disease Control and Prevention (CDC). Incidence of end-stage renal disease among persons with diabetes - United States. 1990-2002. MMWR Morb Mortal Wkly Rep 2005; 54: 1097-1100
2. Banba N, Nakamura T, Matsumura M et al. Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy. Kidney Int 2000; 58: 684-690
3. Sassy-Prigent C, Heudes D, Mandet C et al. Early glomerular macrophage recruitment in streptozotocin-induced diabetic rats. Diabetes 2000; 49: 466-475
4. Schneider A, Panzer U, Zahner G et al. Monocyte chemo-attractant protein-1 mediates collagen deposition in experimental glomerulonephritis by transforming growth factor-beta. Kidney Int 1999; 56: 135-144
5. Hirata K, Shikata K, Matsuda M et al. Increased expression of selectins in kidneys of patients with diabetic nephropathy. Diabetologia 1998; 41: 185-192
6. Okada S, Shikata K, Matsuda M et al. Intercellular adhesion molecule-1-deficient mice are resistant against renal injury after induction of diabetes. Diabetes 2003; 52: 2586-2593
7. Chow F, Ozols E, Nikolic-Peterson DJ et al. Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury. Kidney Int 2004; 65: 116-128
8. Utimura R, Fujihara CK, Mattar AL et al. Mycophenolate mofetil prevents the development of glomerular injury in experimental diabetes. Kidney Int 2003; 63: 209-216
9. Han SY, So GA, Jee YH et al. Effect of retinoic acid in experimental diabetic nephropathy. Immunol Cell Biol 2004; 82: 568-576
10. Guan Y, Breyer MD. Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease. Kidney Int 2001; 60: 14-30
11. Desvergene B, Wahli W. Peroxisome proliferators-activated receptor: nuclear control of metabolism. Endocr Rev 1999; 20: 649-688
12. Willson TM, Lambert MH, Kliewer SA. Peroxisome proliferators-activated receptor gamma and metabolic disease. Annu Rev Biochem 2001; 70: 341-367
13. Kota BP, Huang TH, Roufogalis BD. An overviewon biological mechanisms of PPARs. Pharmacol Res 2005; 51: 85-94
14. Ma LJ, Marcantoni C, Linton MF et al. Peroxisome proliferators-activated receptor-γ agonist troglitazone protects against nondiabetic glomerulosclerosis in rats. Kidney Int 2001; 59: 1899-1910
15. Lee S, Kim W, Kang KP et al. Agonist of peroxisome proliferator-activated receptor γ, rosiglitazone, reduces renal injury and dysfunction in a murine sepsis model. Nephrol Dial Transplant 2005; 20: 1057-1065
16. Baylis C, Atzpodien EA, Freshour G et al. Peroxisome proliferators-activated receptor-γ agonist provides superior renal protection versus angiotensin-converting enzyme inhibition in a rat model of type 2 diabetes with obesity. J Pharmacol Exp Ther 2003; 307: 854-860
17. McCarthy KJ, Routh RE, Shaw W et al. Troglitazone halts diabetic glomerulosclerosis by blockade of mesangial expansion. Kidney Int 2000; 58: 2341-2350
18. Buckingham RE, Al-Barazanji KA, Toseland CN et al. Peroxisome proliferators-activated receptor-γ agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats. Diabetes 1998; 47: 1326-1334
19. Cha DR, Kim JS, Kang YS et al. Urinary concentration of transforming growth factor-β inducible gene-h3 in patients with type 2 diabetes mellitus. Diabet Med 2005; 22: 14-20
20. DeRisi J, Penland L, Brown PO et al. Use of a cDNA microarray to analysis gene expression patterns in human cancer. Nat Genet 1996; 14: 457-460
21. Ma LJ, Nakamura S, Aldigier JC et al. Regression of glomerulosclerosis with high-dose angiotensin inhibition is linked to decreased plasminogen activator inhibitor-1. J Am Soc Nephrol 2005; 16: 966-976
22. Han SY, Kim CH, Kim HS et al. Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. J Am Soc Nephrol 2006; 17: 1362-1372
23. Guan Y, Zhang Y, Davis L et al. Expression of peroxisome proliferator-activated receptor γ (PPARγ) in human transitional bladder carcinoma and its role in inducing cell death. Neoplasia 1999; 1: 330-339
24. Bakris GL, Ruilope LM, McMorn SO et al. Rosiglitazone reduces urinary albumin excretion in type II diabetes. J Hypertens 2003; 17: 7-12
25. Nakamura T, Ushiyama C, Suzuki S et al. Effect of troglitazone on urinary albumin excretion and serumtype IV collagen concentration in type 2 diabetic patients with microalbuminuria or macroalbuminuria. Diabet Med 2001; 18: 308-313
26. Bao Y, Jia RH, Yuan J et al. Rosiglitazone ameliorates diabetic nephropathy by inhibiting reactive oxygen species and its downstream-signaling pathways. Pharmacology 2007; 80: 57-64
27. Yu X, Li C, Li X et al. Rosiglitazone prevents advanced glycation end products-induced renal toxicity likely through suppression of plasminogen activator inhibitor-1. Toxicol Sci 2007; 96: 346-356
28. Pistrosch F, Herbrig K, Kindel B et al. Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients. Diabetes 2005; 54: 2206-2211
29. Ohga S, Shikata K, Yozai K et al. Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-κB activation. Am J Physiol Renal Physiol 2007; 292: F1141-F1150
30. Ha H, Yu MR, Choi YJ et al. Role of high glucose-induced nuclear factor-kappaB activation in monocyte chemoattractant protein-1 expression by mesangial cells. J Am Soc Nephrol 2002; 13: 894-902
31. Makino H, Miyamoto Y, Sawai K et al. Altered gene expression related to glomerulogenesis and podocyte structure in early diabetic nephropathy of db/db mice and its restoration by pioglitazone. Diabetes 2006; 55: 2747-2756
32. Agarwal R. Anti-inflammatory effects of short-termpioglitazone therapy in men with advanced diabetic nephropathy. Am J Physiol Renal Physiol 2006; 290: F600-F605
33. Schmid H, Boucherot A, Yasuda Y et al. Modular activation of nuclear factor-kappaB transcriptional programs in human diabetic nephropathy. Diabetes 2006; 55: 2993-3003
34. Mezzano S, Aros C, Droguett A et al. NF-kappaB activation and overexpression of regulated genes in human diabetic nephropathy. Nephrol Dial Transplant 2004; 19: 2505-2512
35. Igelesias P, Diez JJ. Peroxisome proliferator-activated receptor gamma agonists in renal disease. Eur J Endocrinol 2006; 154: 613-621